Meeting
2014 ASCO Annual Meeting
Clinical outcomes of estrogen receptor (ER)-negative and progesterone receptor (PgR)-positive invasive breast cancer.
Authors
Melissa Chan
Princess Margaret Cancer Centre - University Health Network, Department of Medicine, University of Toronto, Toronto, ON, Canada
Melissa Chan , Martin Chang , Rosa Gonzalez , Belinda Lategan , Elvira del Barco , Francisco Emilio Vera-Badillo , Paula Quesada , Robyn Goldstein , Ignacio Cruz , Alberto Ocana , Juan J. Cruz , Eitan Amir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 567)
DOI
10.1200/jco.2014.32.15_suppl.567
Abstract #
567
Poster Bd #
31
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Trends in breast cancer incidence among young women aged 20 to 49 years in the United States.
First Author: Shuai Xu
Poster
2013 ASCO Annual Meeting
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence.
First Author: Maria Vittoria Dieci
Poster
2023 ASCO Annual Meeting
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.
First Author: Arielle J Medford
Poster
2023 ASCO Annual Meeting
Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor.
First Author: Biyun Wang